More Weight Loss Solutions


Archive for the ‘Human Growth Hormone’ Category

Entera Bio Ltd.

Inventions aim to improve bioavailability and reduce drug costs

Patent applications include optimized oral delivery of specific molecules for various indications

BOSTON and JERUSALEM, May 05, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that it recently filed multiple U.S. patent applications to further strengthen the Companys patent protection and support future developments.

These patent applications address an optimized platform technology intended to be utilized for future therapeutic applications. The modified platform has the potential for a higher bioavailability and lower cost of goods in comparison to competitive technologies used for the oral delivery of peptides. Additionally, the technology is designed to utilize only well-known and approved pharmaceutical excipients and, therefore, we believe it can simplify regulatory approval. In parallel with the platform technology patent, the Company filed several patent applications related to the oral delivery of specific molecules or families of molecules, including parathyroid hormone (PTH), glucagon-like peptide (GLP)-1, GLP-2, human growth hormone (hGH), and others, utilizing the newly optimized oral delivery platform for indications including osteoporosis, hypoparathyroidism, non-union bone fractures, short bowel syndrome, and GH deficiency, and others.

We believe Entera is at the forefront of innovating and improving the oral delivery of large molecule proteins. Weve filed a substantial number of new patent applications intended to fortify our robust intellectual property position as we evaluate engaging in additional strategic partnerships, stated Entera Chief Executive Officer, Spiros Jamas. We see opportunities with GLPs, orphan indications, and the extension of major categories of biologic drugs, which have the potential for oral delivery through Enteras platform. Concurrently, we are working on global partnering of our lead asset, EB613, as it moves toward a pivotal Phase 3 for the treatment of osteoporosis.

Story continues

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Companys proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The Company recently completed the phase 2 study for EB613. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit

Forward Looking Statements

Various statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, anticipate, believe, can, could, expect, estimate, design, goal, intend, may, might, objective, plan, predict, project, target, likely, should, will, and would, or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Enteras forward-looking statements include, among others: changes in our interpretation of the 3-month biomarker data from the Phase 2 clinical trial of EB613, the timing of data readouts from the Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613 and our analysis of the full results from our Phase 2 clinical trial of EB613, the FDAs interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay-offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Enteras agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID-19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the size and growth of the potential market for EB613 and Enteras other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Enteras product candidates including EB612 and GLP-2; Enteras reliance on third parties to conduct its clinical trials; Enteras expectations regarding licensing, business transactions and strategic collaborations; Enteras operation as a development stage company with limited operating history; Enteras ability to continue as a going concern absent access to sources of liquidity; Enteras expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Enteras ability to raise additional capital; Enteras interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Enteras ability to obtain and maintain regulatory approval for any of its product candidates; Enteras ability to comply with Nasdaqs minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Enteras intellectual property position and its ability to protect its intellectual property; and other factors that are described in the Cautionary Statements Regarding Forward-Looking Statements, Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Enteras filings with the SEC and available free of charge on the SECs website at Additional factors may be set forth in those sections of Enteras Annual Report on Form 10-K for the year ended December 31, 2021 (the Annual Report), filed with the SEC in the first quarter of 2022. In addition to the risks described above and in Enteras Annual Report and Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Enteras results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely on the forward-looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Contact:Nicole JonesCG

Read the original:
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics - Yahoo...

Comments Off on Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics – Yahoo…
May 9th, 2022 | Filed under Human Growth Hormone

Hows that New Years Resolution to lose weight coming along? We get it. Most of us have been there. Shedding the pounds while keeping yourself happy and healthy is no easy task. Sure there are alternatives bariatric surgery or laser treatments to name a couple. But why not try a method that does not require going under the knife and is inexpensive? The 21 Day Intermittent Fasting Challenge could be what you need to succeed in your weight loss journey.

So what exactly is Intermittent Fasting? Essentially its just what the name implies. Its an eating pattern that cycles between periods of fasting and eating. It doesnt specify which foods you should eat but rather when you should eat them. Not only can it help you lose weight and visceral fat, but it has also been known to reduce the blood levels of insulin in your body while increasing the human growth hormone levels. It has been shown to improve blood pressure and triglycerides, reduce the risk of cancer, and help to prevent Alzheimers, among other benefits.


This 21 Day Intermittent Fasting Challenge gets you started on the road to a healthier you. You will receive a meal plan that includes 2 meals and one snack daily, plus an overview of what food you can and should not eat. You will learn about potential side effects and how to avoid them, plus be introduced to a variety of fasting methods. You can customize your intake depending on your diet of choice there are Keto, vegan, Paleo, vegetarian, and Vegan Keto plan options available.

Best of all, you will not be doing this alone. Once you sign on, you will become part of an exclusive community of like-minded people from all around the world with whom you will be able to share your successes, ask questions, or look for guidance.

So stop procrastinating. By doing this challenge, and pairing it with a good exercise program, you could be very pleasantly surprised by the results. Get lifetime access to the 21 Day Intermittent Fasting Challenge for only $19, an 80% discount off the regular suggested retail price.


Prices subject to change.

Read more from the original source:
Start on the road to a healthier you with the 21-Day Intermittent Fasting Challenge for only $19 - WDIV ClickOnDetroit

Comments Off on Start on the road to a healthier you with the 21-Day Intermittent Fasting Challenge for only $19 – WDIV ClickOnDetroit
Apr 26th, 2022 | Filed under Human Growth Hormone

Market Overview

The Global Protein Therapeutics Market is expected to cross USD 290,691.88 Million by 2027 at a CAGR of 6.86%.

Market Dynamics

One of the most important classes of pharmaceuticals is therapeutic protein therapies. These medications are used to treat and manage a variety of conditions, including cancer and infectious infections. Protein therapeutic medicines offer a great deal of promise to improve human health, thus demand for these treatments is expected to skyrocket in the future. During the projected period, the increased prevalence of chronic diseases such as diabetes is expected to have an impact on the protein therapies markets growth. Rapid technological breakthroughs in the field of protein therapies are expected to have a beneficial impact on demand. During the forecast period, increased awareness of protein therapies is expected to fuel the global protein therapeutics markets growth. Protein therapeutics market growth is expected to be boosted in the near future by the increased use of plasma-derived medicines for the treatment of chronic diseases. Increased government measures to strengthen the healthcare sector are projected to create favourable conditions for the protein therapies market to grow.

During the projected period, however, the tight regulatory environment governing product approval is expected to restrain the growth of the protein therapies market. Protein treatments market expansion is projected to be constrained by their high cost.

Sample Report:

Segmental Analysis

The market for protein therapeutics has been divided into three categories: type, application, and end user.

Monoclonal antibodies, insulin, fusion proteins, erythropoietin, interferon, human growth hormone, follicle-stimulating hormone, and others are among the products available. Because of the rising prevalence of diabetes around the world, the insulin segment is the fastest-growing.

The worldwide protein therapies market has been divided into cancer, metabolic diseases, immunologic disorders, haematological disorders, and others based on application. Because of the increased frequency of cancer around the world, the cancer segment accounts for a substantial portion of the worldwide protein therapies market.

The global protein therapies market has been divided into hospitals and clinics, specialty centres, and others based on the end user. During the projected period, the hospitals and clinics segment is expected to develop due to an increase in hospital admissions and the increased prevalence of chronic diseases.

Regional Overview

During the review period, the Americas was the largest regional market. The demand for therapeutic proteins is expanding as a result of increased government initiatives and growing concerns about healthcare workers health and safety. Moreover, one of the primary factors driving the protein therapies market over the forecast period is the increased prevalence of cancer. With such a big patient population, the global protein therapies market is expected to increase significantly in the near future.

During the forecast period, the western European healthcare market, which includes Germany, the United Kingdom, France, and Italy, is expected to see an increase in healthcare expenditure, as well as an increase in cases of rheumatoid arthritis, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy, resulting in the growth of the protein therapeutics market. During the forecast period, it is expected to enhance the growth of the protein therapies market.

The fastest-growing geographical market is Asia-Pacific. Emerging market participants in previously untouched regions, increased R&D in the protein therapeutics segment, the governments increased focus on immunisation to avoid various diseases, and a large target population are all factors impacting market expansion. One of the primary factors driving the regions protein therapies market growth is the expanding elderly population.

The expansion of the protein therapeutics market in the Middle East and Africa is likely to be fueled by government efforts and increased investments in the healthcare sector in the UAE and South Africa.

Access Report Details @

Competitive Dynamics

The notable players of the market are Abbott Laboratories (US), Amgen Inc. (US), Baxter International Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Johnson & Johnson (US), Merck & Co., Inc. (US), Novo Nordisk A/S (Denmark), CSL Behring (US), Bristol Myers Squibb Co. (US), Pfizer Inc. (US), Sanofi (France), and Biogen, Inc. (US).

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Get More Related Reports:


Market Research Future

99 Hudson Street,5Th Floor

New York, New York 10013

United States of America


+1 628 258 0071(US)

+44 2035 002 764(UK)

Email: [emailprotected]

Read more:
Protein Therapeutics Market Report 2023 Market SWOT Analysis, Key Indicators, Forecast 2027. - Digital Journal

Comments Off on Protein Therapeutics Market Report 2023 Market SWOT Analysis, Key Indicators, Forecast 2027. – Digital Journal
Apr 26th, 2022 | Filed under Human Growth Hormone

New York, April 11, 2022 (GLOBE NEWSWIRE) -- announces the release of the report "Global Human Growth Hormone Market 2022-2026" - 44% during the forecast period. Our report on the human growth hormone market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the development of long-acting and needle-free deliveries to improve adherence, FDA approval of human growth hormone replacement therapy for new indications, and a strong pipeline of human growth hormone.The human growth hormone market analysis includes application segment and geographic landscape.

The human growth hormone market is segmented as below:By Application Growth hormone deficiency ISS Turner syndrome PWS Others

By Geographical Landscape North America Europe Asia Rest of World (ROW)

This study identifies the increasing incidence of growth disorders as one of the prime reasons driving the human growth hormone market growth during the next few years. Also, no impact of biosimilar entry into the market, and advanced technologies will lead to sizable demand in the market.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the human growth hormone market covers the following areas: Human growth hormone market sizing Human growth hormone market forecast Human growth hormone market industry analysis

This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human growth hormone market vendors that include Abbott Laboratories, Anhui Anke Biotechnology Group Co. Ltd., Ascendis Pharma AS, F. Hoffmann La Roche Ltd., Ferring B.V., Ipsen Pharma, Merck and Co. Inc., Novo Nordisk AS, and Pfizer Inc. Also, the human growth hormone market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.Read the full report:

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Go here to read the rest:
The Global Human Growth Hormone Market is expected to grow by $ 1.16 bn during 2022-2026 progressing at a CAGR of 5.44% during the forecast period -...

Comments Off on The Global Human Growth Hormone Market is expected to grow by $ 1.16 bn during 2022-2026 progressing at a CAGR of 5.44% during the forecast period -…
Apr 12th, 2022 | Filed under Human Growth Hormone

Short stature is a main problem in Noonan syndrome (NS). Recombinant human growth hormone (GH) has been used to safely improve the growth rate in NS patients with short stature. However, there is little information about GH therapy for NS associated with hypertrophic obstructive cardiomyopathy. We present the case of a seven-year-old NS patient with severe hypertrophic obstructive cardiomyopathy. The patient received GH therapy for six months, at which time progressive left ventricular outflow tract stenosis was apparent.

Noonan syndrome (NS) is an autosomal dominant disorder that is characterized by short stature, craniofacial dysmorphism, congenital heart disease, skeletal abnormalities, developmental delay, hematologic disorder, and other abnormalities [1]. The most common cardiovascular problems in NS are pulmonary valve stenosis, hypertrophic cardiomyopathy (HCM), and atrial septal defect.

Short stature affects 50%-70% of patients with NS and is one of its main diagnostic features [2]. Patients with NS receive growth hormone (GH) therapy to treat short stature [3,4]. One of the main concerns about GH treatment is the presence of HCM because patients with acromegaly and a chronic excess of GH and insulin-like growth factor-1 (IGF-1) exhibit biventricular hypertrophy [2,5]. In multiple clinical trials that included patients with HCM, there was no evidence to support a higher prevalence of cardiac comorbidities, and GH treatment was shown to be safe [2,4]. However, there is insufficient information about GH therapy in NS associated with HCM [6].

We report the case of a seven-year-old male NS patient with severe hypertrophic obstructive cardiomyopathy (HOCM) who received GH therapy that resulted in progressive left ventricular outflow tract stenosis (LVOTS).

A seven-year-old male was born full term and was the first child. Because thickening of the left ventricular wall was observed in utero, he was admitted to the neonatal intensive care unit after birth. An echocardiogram showed HCM without left ventricular outflow tract stenosis. At two months of age, the patient was discharged and started on diuretics and propranolol with careful cardiac follow-up.

On the basis of the patients clinical findings, NS was suspected. Genetic testing revealed a heterozygous missense variant on exon 7, c.770C>T (p.S257L) in RAF1. Genetic testing of the patients parents found that no mutations were present. Thus, the NS diagnosis was confirmed.

Despite receiving medication, the echocardiogram showed that the LVOTS had worsened, and the patient exhibited HOCM. Diagnostic cardiac catheterization was performed and showed a pressure gradient from the left ventricular apex to the ascending aorta that was 60 mmHg at two years of age. When the patient was three years old, septal myotomy-myectomy was performed to treat the LVOTS. After surgery, peak velocity of the left ventricular outflow tract was improved and mitral regurgitation was mild.

When the patient was four years and six months old, patients height and weight were 87.7 cm (3.85 standard deviation [SD]) and 13.35 kg (1.75 SD), respectively. GH treatment was started at the guardians request despite severe HCM. Before GH treatment, he was referred to the pediatric cardiologist. The echocardiogram results showed left ventricle dimension diastole of 23.5 mm, ejection fraction of 74.7% and left ventricle (LV) wall thickness at diastolic phase of 8.5 mm, mild mitral regurgitation, and mild LVOTS (peak velocity of the left ventricular outflow tract was 2.9 m/s) (Figures 1A, 2A). A GH stimulation test revealed GH deficiency (GHD) (Table 1). Table 2 shows the patients laboratory data before GH treatment. White blood cell fraction results were negative for juvenile myelomonocytic leukemia. Based on these results, the GH dose at the start of therapy was 0.088 mg/kg/week (half the dose for GHD).

Cardiac follow-up was performed during GH treatment. When the patient was five years old, a follow-up echocardiogram showed progressive LVOTS (peak velocity of left ventricular outflow tract was 5.0 m/s) and progressive mitral regurgitation due to systolic anterior movement (Figures 1B, 2B). Although the patient was re-prescribed propranolol to treat LVOTS, echocardiogram results showed preserved left ventricular contraction (left ventricle dimension diastole of 30.6 mm, ejection fraction of 59.8%), increased LV wall thickness (LV wall thickness at diastolic phase of 11.4 mm), and left ventricular outflow tract velocity worsened (peak left ventricular outflow tract velocity was 5.8 m/s) at five years and seven months of age. GH treatment was stopped due to progressive LVOTS.

The patient is now seven years old, and his mitral regurgitation and LVOTS have not worsened.

We present the case of a NS patient with severe HCM who underwent septal myotomy-myectomy. The patient received GH treatment for short stature, and after starting GH, LVOTS progressed.

Several clinical trial results indicated that GH therapy is safe for as long as cardiac follow-up is performed during GH therapy. Some clinical trials have included patients with NS complicated by HCM [4]. In a previous report, the effects of growth hormone on the left ventricular wall in patients with NS, including one patient with HOCM, were studied for five years, but the left ventricular wall thickness did not change [3,4].

In our case, the patient exhibited a severe HCM phenotype due to RAF1 gene mutations, and low-dose GH was administered [7]. Because the number of cases is small and HOCM severity is unclear in previous reports, information about GH treatment for severe HCM was limited [2]. For NS patients with severe HCM, current knowledge is insufficient to conclude if GH treatment is safe in patients with NS and pre-existing severe HCM. The cause of LVOTS progression in our patient is unclear, but it may have occurred after GH treatment was started, and GH may have had an effect on LVOTS. Further careful study is warranted to examine GH therapy side effects in NS patients with severe HCM.

GH treatment is a safe and effective therapy for NS patients for short stature. However, GH therapy for patients with severe HCM is not well understood. Cardiologists should be mindful that careful use of GH therapy will be required in patients with NS and pre-existing severe HCM.Frequent cardiac follow-up during GH therapy is also necessary.

Here is the original post:
Progressive Left Ventricular Outflow Tract Stenosis in a Noonan Syndrome Patient With Severe Hypertrophic Cardiomyopathy During Growth Hormone...

Comments Off on Progressive Left Ventricular Outflow Tract Stenosis in a Noonan Syndrome Patient With Severe Hypertrophic Cardiomyopathy During Growth Hormone…
Apr 12th, 2022 | Filed under Human Growth Hormone

When you have diabetes, insulin is vital to helping you keep your blood sugar levels in check.

If you have type 1 diabetes, you must inject insulin daily. Those with type 2 diabetes may also require insulin injections to maintain their blood sugar levels.

Not all insulin types are the same. Pharmaceutical manufacturers make long-acting, intermediate-acting, and short-acting insulin options. If you do inject insulin, the best way to start a treatment plan is to contact your doctor.

In people who do not have diabetes, their bodies release insulin in response to the foods they eat. This is because many foods contain carbohydrates. Some examples include bread, sweets, fruits, and even vegetables.

Your body breaks carbohydrates down into smaller building blocks, like glucose. You need insulin to use this glucose for energy. If your body cannot make or use insulin effectively, youll need to inject it to process your food for energy.

Calculating how much insulin to take is usually based on two considerations:

Anticipating a bolus dose is where insulin administration can get tricky. When you give yourself insulin, you are estimating how many units of insulin it will take to process the carbohydrates you eat.

The University of California, San Francisco states that, as a general rule, 1 unit of insulin will process anywhere from 12 to 15 grams of carbohydrates and lower your blood sugar by about 50 milligrams per deciliter (mg/dL).

Since the human body is so complex, not all people will process insulin the same way. Factors like time of day, stress levels, and physical activity can make these numbers more difficult to predict.

Because of this, youll probably start off giving yourself insulin based on numbers for the average person. After seeing how these numbers help you manage your blood sugar, you may have to adjust based on how your body uniquely responds to the insulin you administer.

Now that you know the how and why behind insulin dosing, lets consider how you may calculate your insulin needs.

Youll usually give yourself an insulin dose around your meals since thats when you take in carbohydrates. You also will typically check your blood sugar to see if youre meeting your premeal target dose.

To calculate your insulin needs:

You may find that if you generally eat about the same amount of carbohydrates each day, you may be able to consistently inject the same amounts of insulin outside of special occasions. It takes time to find out how your body best responds to insulin.

Remember, there are two components to insulin correction:

Combine both of these when considering how much insulin to inject.

For this chart, well assume that your premeal blood sugar target is 120 mg/dL and that 1 unit will decrease your blood sugar by 50 points.

If your blood sugar is below 60, do not administer insulin. Instead, you should immediately consume 15 grams of carbohydrates.

If your blood sugar is 300 and above, check your ketones and contact your doctor immediately.

For this chart, well assume that you take 1 unit of insulin for every 10 grams of carbohydrates.

How diabetes affects your body can vary greatly from person to person and day to day.

When establishing your insulin routine with your doctor, be sure to discuss your lifestyle honestly so they can help create the best plan for you. Your doctor might advise different calculations than those listed above to help fine-tune your dosage.

Many things can affect how your body processes carbohydrates and insulin. According to the American Diabetes Association, these include:

Insulin has a narrow therapeutic index, which means there is a fine line between a beneficial dose and a harmful one.

Its possible to overdose on insulin. In a review of insulin overdoses, excess dosages were reported as being anywhere from 26 to 4,800 units. Some of these were administered accidentally, which helps explain why the number is so high.

Its important to know the symptoms of hypoglycemia in case you ever inject too much insulin. These include:

Contact your doctor if youve over-administered your insulin.

Ideally, you should be able to correct your blood sugar with an appropriate insulin dose. How much insulin is too much varies based on how sensitive your body is to insulin.

If you have higher-than-expected blood sugar (over 300), you should check your urine for ketones. The presence of ketones suggests your bodys cells are having trouble getting enough glucose. You could be at risk for a serious condition called diabetic ketoacidosis (DKA) if you have ketones in your urine.

In this instance, you need extra help correcting your blood sugar. You should seek emergency medical attention instead of trying to keep injecting insulin to lower your blood sugar.

Insulin will lower your blood sugar. If your blood sugar is already low, you shouldnt inject more insulin.

Signs that your blood sugar is too low include sweating, dizziness, blurred vision, and significant fatigue. If this happens, try to consume rapid-acting carbohydrates, like sugared sodas, fruit juice, or glucose tablets, to get your blood sugar levels back up quickly.

You can calculate the amount of insulin you take before meals by considering your blood sugar before you eat and the number of carbohydrates you take in during your meal. Scroll up to see our sample calculation and example.

The average person will take about 1 unit of insulin for every 12 to 15 grams of carbohydrates consumed.

There is some variation to this, depending on how sensitive you are to insulin. For some people, this range is 1 unit for every 6 grams of carbohydrates, while for others, its 1 unit for every 30 grams of carbohydrates.

You will typically inject a longer-acting or basal insulin at night. This insulin will work as you sleep for (ideally) seven to eight hours. You should establish your basal insulin dose with your doctor.

You may adjust this dose on a regular basis depending on your blood sugar before bed.

Injecting insulin is not a safe approach to weight training. However, some bodybuilders will inject it as a performance-enhancing drug. They believe injecting insulin will allow energy in the form of glucose to enter their cells so they can build more muscle.

This practice is unsafe and can lead to severe and potentially life threatening hypoglycemia, according to 2019 research.

You should not take insulin unless you have diabetes. If you do have diabetes, talk with your doctor about how your training regimen may affect your blood sugar levels.

Human growth hormone (HGH) is another hormone that bodybuilders may inject in an attempt to gain muscle. Some bodybuilders will inject both HGH and insulin, according to 2017 research. This is an unsafe practice that doctors do not recommend.

It can take time to understand how your body best responds to insulin correction when you have diabetes.

Having a plan for regular dosage and knowing the signs of high and low blood sugar can help you safely manage your diabetes. If you have questions, contact your doctor to ensure you have the best plan for keeping your blood sugar under control.

Here is the original post:
How Much Insulin to Take: Easy Chart and Explanation - Healthline

Comments Off on How Much Insulin to Take: Easy Chart and Explanation – Healthline
Apr 12th, 2022 | Filed under Human Growth Hormone

Human growth hormone (hGH) is a proteohormone secreted by the pituitary gland. It acts through binding to the hGH receptor, inducing either direct effects or initiating the production of insulin-like growth-factor I (IGF-I), the most important mediator of hGH effects. Growth hormone is primarily known to promote longitudinal growth in children and adolescents, but has also various important metabolic functions throughout adult life. Effects of hGH on the adult organism are well established from studies with recombinant growth hormone (rhGH) therapy in growth hormone deficient subjects. In this particular group of patients, replacement of hGH leads to increased lipolysis and lean body mass, decreased fat mass, improvements in VO(2max), and maximal power output. Although extrapolation from these findings to the situation in well trained healthy subjects is impossible, and controlled studies in healthy subjects are scarce, abuse of hGH seems to be popular among athletes trying to enhance physical performance. Detection of the application of rhGH is difficult, especially because the amino acid sequence of rhGH is identical to the major 22,000 Da isoform of hGH normally secreted by the pituitary. Furthermore, some physiological properties of hGH secretion also hindered the development of a doping test: secreted in a pulsatile manner, it has a very short half-life in circulation, which leads to highly variable serum levels. Concentration alone therefore cannot prove the exogenous administration of hGH.Two approaches have independently been developed for the detection of hGH doping: The so-called "marker approach" investigates changes in hGH-dependent parameters like IGF-I or components of bone and collagen metabolism, which are increased after hGH injection. In contrast, the so-called "isoform approach" directly analyses the spectrum of molecular isoforms in circulation: the pituitary gland secretes a spectrum of homo- and heterodimers and - multimers of a variable spectrum of hGH isoforms, whereas rhGH consists of the monomeric 22,000 Da isoform only. This isoform therefore becomes predominant after injection of rhGH. Specific immunoassays with preference for the one or the other isoform allow analysis of the relative abundance of the 22,000 Da isoform. Application of rhGH can be proven when the ratio of this isoform relative to the others is increased above a certain threshold. Because the "marker method" and the "isoform method" have a different window of opportunity for detection, complementary use of both tests could be a way to increase the likelihood of detecting cheating athletes.

Read more:
Growth hormone - PubMed

Comments Off on Growth hormone – PubMed
Dec 30th, 2021 | Filed under Human Growth Hormone

Overview Kenai Farms CBD Gummies Reviews & Cost

Kenai Farms CBD Gummies Reviews: In these times, when the world is changing so rapidly and everything is moving so fast, it would be quite miraculous to dodge any kind of stress and lead a healthy and happy life. With increasing age, the stress increases and so does the joint pains and chronic aches. These issues create a big hindrance in our daily lives.


Now, one of the most effective supplements to deal with these issues are considered to be CBD based food supplements. The CBD supplements are popular and very helpful in dealing with stress, anxiety and relieving pain. There are several such products available in the market these days as well.

But the question arises that are these supplements really safe? There is no denying in the fact that the food which has CBD supplements connect to marijuana and may cause psychoactive effects such as a sensation of being high.

Therefore, it is difficult and essential to find a product that is safe and effective.

Kenai Farms CBD Gummies are a candidate in that field. Let us have a look at this product in a bit more detail.

Kenai Farms CBD Gummies is an organic food supplement. This dietary supplement contains full-spectrum CBD. All the ingredients are 100% natural to ensure quality and safety. CBD Gummies are using by the people all over the world these days to relieve stress and anxiety and deal with chronic and joint pains. This food supplement has FDA certificate that clears that it ensures safety. Even though it is a product containing CBD, it does not contain marijuana or large amounts of THC. Therefore, it is non-addicting and does not have any effects of high sensation.

CBD Gummies are manufactured in the United States of America at an FDA approved facility, following all the good manufacturing practices. It is a non-GMO product and is free from any kind of artificial fillers. Kenai Farms CBD Gummies is a safe to use product, without any intoxicating or addicting property.

Kenai Farms CBD Gummies have all the natural ingredients that have stress relieving properties. The key ingredients of this full spectrum CBD food supplement are melatonin and, of course, CBD. Let us have a look at the role of these two contents in a bit detail:

CBD: Cannabinoid, without any doubt, is the most well-known and the most widely used ingredient in supplements to relieve stress and anxiety as well as chronic aches. CBD is a extract that comes from the hemp plant and relieves stress by releasing into the ECS (Endocannabinoid System).

The ECS is the central system in the body that is responsible for the smooth inner functioning as well as for regulating mood and providing pain relief.

The ECS receptors CB1 (found in the central nervous system) and CB2 (present in certain peripheral tissues) receive the signals from the ECS and transmits them, resulting in the corresponding response and relief or functioning.

The CBD added in Kenai Farms CBD Gummies is based on hemp extract and does not create any harmful psychoactive effect. Moreover, it also enhances good sleep and improves metabolism.

Melatonin: Melatonin helps in getting proper sleep. In fact, it is used in several medicines to deal with insomnia. In addition to this, it also helps in improving the immune system, manages blood pressure and cortisol levels. It can also act as an antioxidant.

Moreover, melatonin has been proven quite effective in dealing with seasonal depression. Melatonin is also known to have an effect in increasing the levels of HGH (Human Growth Hormone). It also improves eye health and may help treat GERD (Gastroesophageal Reflux Disease). Hence melatonin is the Midas of ingredients when it comes to developing a healthy food supplement.

Kenai Farms CBD Gummies are natural and safe. People often worry that the CBD based supplements often lead to intoxication. But that is not the case with CBD Gummies. That is because it contains only trace amount of THC, only about 0.03%, which is quite negligible and hence ineffective in causing any psychoactive effects or a high sensation.

Special Discount: Check High Discount Price Available For Kenai Farms CBD Gummies

Kenai Farms CBD Gummies have not one but multiple health benefits. some of the health benefits are as follows:

As we know, Fun Drops CBD Gummies have all the natural ingredients only, there are no harmful side effects of this product. This dietary supplement is using by people all over the globe and there have not been even a single case of any serious health issue or side effect of using this supplement.

In fact, this product is clinically tested and approved to ensure safety. Moreover, all the ingredients are grown and harvested in the United States of America. This ensures quality of the product. Also, it is a vegan product and easy to take by everyone.

The biggest fear that people generally have in their mind while consuming a CBD based product is that it might lead to some psychoactive effects. But Kenai Farms CBD Gummies do not cause any such effect or any high sensation. That is because it contains only trace amount of THC, less than 0.03%.

Therefore, this product is safe to use.

It is always better to follow certain safety precautions while consuming any medication or food supplements to ensure safety. These are some of the safety measures you must keep in mind while consuming the Kenai Farms CBD Gummies:

Usually 1-2 gummies are advisable, as per the pack of Kenai Farms CBD Gummies. You can take one gummy in the morning and one gummy in the evening, preferably with a glass of milk. You can also consult a physician before consuming these gummies and then follow the dosage instructions prescribed by them.

Kenai Farms CBD Gummies are easily available on the official website. When you visit their website, you will find multiple offers and packages on this product, depending on the quantity of Pure Potent bottles you buy. You can select the package as per your choice and requirement. After that, you will be presented with several payment options.

Choose the most feasible payment option and make payment. Provide your shipping address and place the order. Order your product and your CBD Gummies Australia bottle will come at your doorstep within 7-10 business days.

CBD Gummies also provide easy return policies to ensure best customer service. So, if you want to return the product, you can raise a request within 1 month of buying the product, no questions asked. The money will be refunded within 15 days. Therefore, this product guarantees 100% results.

These days when most CBD products cause serious effects on your mental health, or makes you dizzy or tired, it is very rare to find a product that helps you deal with your stress and anxiety without causing any other ill effect on your health. Kenai Farms CBD Gummies is one of those rare products that improve your mental as well as overall health in a natural manner, without causing any side effect or a sensation of being high. This product is safe to use and is proving its worth worldwide by giving the most positive outcomes.

Special Discount: Check High Discount Price Available For Kenai Farms CBD Gummies

2021 LLP

Media Contact Website:

Media Contact Email:

Go here to read the rest:
Kenai Farms CBD Gummies Reviews (Price 2022) Cost & Website Review | Best CBD Gummies for Anxiety - Journal of the San Juan Islands

Comments Off on Kenai Farms CBD Gummies Reviews (Price 2022) Cost & Website Review | Best CBD Gummies for Anxiety – Journal of the San Juan Islands
Dec 30th, 2021 | Filed under Human Growth Hormone

Regular aerobic exercise has been shown to boost heart health, keep blood sugar levels in check, and maintain the health of our minds for the long haul. But just as there are a multitude of ways to work out and keep your body (and mind) healthy and strong, there are a trove of different approaches you can take to doing cardio. Enter: HIIT, or high-intensity interval training.

HIITs definition is a heckuva lot more simple than you might think, says Annie Mulgrew, founding instructor for CITYROW in New York City and NASM-certified CPT. High-intensity interval training is a form of interval training that alternates between short bursts of intense energy or activity followed by minimal rest, ideally until that person is unable to continue, she explains.

And, as Mulgrew notes, HIIT can be just about anythingfrom swimming to running to mountain climbers in your apartment to even weight training. The key, she says, is ensuring that the short burst of energy is at least 80 percent of your maximum effort (so, 8 on a scale of 10).

For HIIT to be effective, your on intervals need to be all-out, she says. Mulgrew also notes that your rest period shouldnt exceed your active period (try, 20 seconds on and 10 seconds off). That rest period can contain no movement or moderate-effort movementthat part really isnt important, she says. Those maximum-effort bursts are where the gains are made, Mulgrew reiterates.

This content is imported from {embed-name}. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

In Mulgrews CITYROW classes, for example, that on/off scheme translates to both meters rowed on the rowing machine, as well as resistance training off the rower. You may find short rowing distance repeats or hip thrusters programmed as 40 seconds on and 20 seconds off, she says.

If youre using weights for your HIIT workout, choose a weight that allows you to complete 10 to 20 reps repeatedly in your on periods, Mulgrew recommends. Beginners should aim for no more than 20 minutes of HIIT total. And if youre a total HIIT nut, keep it no longer than 50 to 60 minutes (so the actual HIIT portion of the workout is around 30 minutes and the warm-up/cool-down roughly 20 minutes). Going any longer than that would most likely mean youre not able to maintain the intensity you need in order to achieve the benefits of a HIIT workout, she says.

Speaking of benefits, here are five major health perks associated with HIIT, plus, how to maximize your next interval workout.

Although aerobic exercise is a great tool in maintaining your heart health, as far as weight loss tactics go, that steady-state run isnt the best calorie-burner. And while weight training is typically the most reliable weight loss tactic when it comes to fitness type (remember though, weight loss is achieved through a calorie deficit, which is most easily achieved through diet), if there is one form of cardio that blasts calories, its HIIT.

One 2015 study (of healthy men) that compared calorie burn after 30 minutes of HIIT to other forms of steady-state exercise noted that HIIT burned 25 to 30 percent more calories. Other studies (also on men) have noted that HIIT propels your production of human growth hormone, or HGH, upwards of 450 percent in the 24 hours following a session, increasing overall calorie burn.

Yepa study in Journal of Diabetes Research confirmed this. The researchers divided obese, sedentary women into groups: those who partook in a HIIT program and those who did a moderate-intensity (but continuous energy expenditure) routine. The former group achieved similar body composition and aerobic capacity results in half the time.

One major (assumed) drawback to HIIT, of course, is the notion you need to be flying, flailing, bounding, and sprinting (with a series of complicated tools, no less) in order to achieve a solid workout. But as Mulgrew points out, the hallmark of HIIT lies in exertion, not the modality, so pretty much any form of exercise fitsand that includes the simplest form of cardio there is: walking.

In one Japanese study, for five months, 700 middle- and older-aged adults engaged in walking intervals (shorter bursts of speed interspersed with periods of rest). At the conclusion of the study, the individuals had noticeably improved endurance and strength.

Studies have shown that regular HIIT exercise can boost your memory and make you sharper in everyday decision-making. One (potential) reason why, according to Mulgrew: During a HIIT workout, you have to stay focused, she explains.

And, whats more, you dont have to sweat for very long in order to see results. A 2006 study compared two groups of college men for two weeks: those who did stationary bicycling at a moderate pace for roughly an hour-and-a-half to two hours for three times a week, and those who did six 30-second all-out sprints with four minutes of recovery.

Surprise, surprise: The HIIT-ers were just as fit (in terms of exercise performance and muscle growth) as those moderate-intensity exercisers by the end of the trialwith far less time invested.

Here, Mulgrew shares her top tips for ensuring you blast through your next HIIT session.

Be sure to warm up for at least five minutes prior to jumping in.

How to: Start standing with feet just wider than hips, a kettlebell in right hand, right arm bent with elbow close to body so that the weight rests on shoulder, and left hand on hip. Sink hips slightly into a quarter-squat. Then, quickly push through feet to extend legs, simultaneously pressing kettlebell straight up until right arm is completely extended overhead. With control, lower kettlebell back down. That's one rep. Perform as many reps as possible for 45 seconds, then rest for 20 seconds. Repeat for five rounds.

How to: Start in a high plank, shoulders over wrists, pelvis tucked, and ribs drawn toward hips. Drive your right knee toward your chest, then the left. Pull your right knee back toward your chest and pause. Repeat the pattern starting with the left knee. Aim completing 45 seconds of work, followed by 15 seconds of rest. Complete for five rounds.

How to: Start in a low plank with forearms on the floor and parallel, elbows under shoulders. Pick up right forearm and press through palm to extend arm straight. Then, repeat with left to come into a high plank, keeping hips as level as possible. Reverse the movement to return to start. That's one rep. Perform as many reps as possible for 50 seconds, then rest for 10 seconds. Repeat for five rounds.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at

Read the rest here:
5 Benefits Of HIIT - How To Do High-Intensity Interval Training - Women's Health

Comments Off on 5 Benefits Of HIIT – How To Do High-Intensity Interval Training – Women’s Health
Dec 20th, 2021 | Filed under Human Growth Hormone

Cancer Therapeutics and Biotherapeutics Market: Overview

As per the World Health Organization (WHO), approximately 8.2 mn deaths that took place in 2012 were caused due to cancer. The increasing proliferation of novel approaches and personalized medicines growing demand are amongst the prime factors providing impetus to the global cancer therapeutics and biotherapeutics market. In addition to the chemotherapy market, this market is also dominated by biotherapy, which has come up as a new approach in the treatment of cancer. Biotherapy positively impacts the immune system of the human body and impedes or slows down the development of cancer cells. It includes kinases, interferons or interleukin, and monoclonal antibodies.

This study present a detailed evaluation of the cancer therapeutics and biotherapeutics market and presents quantitative evaluation of current market scenario. The factors fuelling and inhibiting the development of this market have also been collated under this report. The trends seen in the dominant regions will aid companies in planning their strategies accordingly. The report also encapsulates the late stage development and the currently marketed cancer products.

Request Brochure of Report -

The list of products in development stage and the present trends and issues impacting the cancer therapeutics and biotherapeutics market have also been presented. The report also encapsulates an extensive mapping of the competitive landscape of the market incorporating the behavior of market participants. Analysis tools such as Porters five forces model, etc. have also been incorporated in order to present the competition present in the cancer therapeutics and biotherapeutics market.

Cancer Therapeutics and Biotherapeutics Market: Drivers and Restraints

The global cancer therapeutics and biotherapeutics market is fuelled by the introduction of products such as gemcitabin, oxaliplatin, and pemetrexed. In addition, the new applications approval for the utilization of these products will positively impact the development of the market. Furthermore, the increasing investments from key players in this market and their increasing focus on lowering the side effects caused by traditional methods of treatment will stimulate the development of this market.

Request for TOC @

The rising count of favorable policies introduced by governments globally toward proper screening, diagnosis, and treatment of cancer will also work in favor of the growth of the overall market. Additionally, the presence of better research and development activities will positively impact the growth of the cancer therapeutics and biotherapeutics market. The increasing occurrence of different types of cancer and the increasing proliferation of new players in this market are predicted to bring in new growth opportunities in the global cancer therapeutics and biotherapeutics market. The introduction of advanced methods of treatment will also provide impetus to the growth of this market. On the other hand, the growing side of effects of traditional treatment technology such as chemotherapy may inhibit the development of this market in the coming years.

Cancer Therapeutics and Biotherapeutics Market Report at

Cancer Therapeutics and Biotherapeutics Market: Region-wise Outlook

On the basis of geography, the report categorizes the global cancer therapeutics and biotherapeutics market into North America, Asia Pacific, Europe, and Rest of the World (RoW).

Key players Mentioned in the Report are:

The top players in this market are Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly & Company, Merck & Company Inc., Johnson & Johnson, Novartis AG, Roche, Pfizer Inc., and Sanofi, among others.

Browse more Reports by Transparency Market Research:

Influenza Medication Market: Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. It is a viral infectious disease that includes three major types: type A, type B, and type C. The common symptoms of the disorder are cold, cough, fever, and sore throat, which can be severe or mild.

Human Growth Hormone Market: Human growth hormone is responsible for growth and regeneration among humans and also stimulates cell reproduction. However, deficiency of growth hormone is constantly on the rise. Advancements in technology including development of recombinant human growth hormone by the major players is boosting the market growth.

Dental Endodontics Market: Endodontics is the division of dentistry which deals with the study and treatment of the dental pulp. Endodontic treatment is also known as root canal treatment, which treats the soft pulp tissue inner side of tooth which is damaged by the infection. Endodontic treatment is conducted by an endodontist.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite:

Originally posted here:
Cancer Therapeutics and Biotherapeutics Market: Increasing occurrence of different types of cancer to drive the market - BioSpace

Comments Off on Cancer Therapeutics and Biotherapeutics Market: Increasing occurrence of different types of cancer to drive the market – BioSpace
Nov 6th, 2021 | Filed under Human Growth Hormone
Weight Loss Solutions